Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real world study of Huazhougan granules
ChiCTR2400084901Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Jul 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of huazhi rougan granule in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: Albuminous aminotransferase (ALT) and Main clinical symptoms score. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
huazhi rougan granule
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2400084901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084901.